• Male or female subjects ≥18 years old or other legal maturity age according to the country of residence

• Confirmed GI (colorectal, pancreatic, gastric, esophageal, gastro-esophageal junction or hepatobiliary) or confirmed GU (renal, ureteral, bladder, prostate, or urethra) cancers if:

‣ Unresectable, locally advanced, metastatic, or non-metastatic GI/GU cancer and

⁃ No intended curative surgery during the study

• Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava vein thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery. Patients are eligible within 120 hours from diagnosis of the qualifying VTE.

• Anticoagulation therapy with LMWH for at least 6 months is indicated

• Able to provide written informed consent